MX2021010809A - Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. - Google Patents
Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma.Info
- Publication number
- MX2021010809A MX2021010809A MX2021010809A MX2021010809A MX2021010809A MX 2021010809 A MX2021010809 A MX 2021010809A MX 2021010809 A MX2021010809 A MX 2021010809A MX 2021010809 A MX2021010809 A MX 2021010809A MX 2021010809 A MX2021010809 A MX 2021010809A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- region
- heterodimeric
- fused
- heterodimer
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 239000000833 heterodimer Substances 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 14
- 108090000623 proteins and genes Proteins 0.000 abstract 14
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una proteína fusionada a un Fc heterodimérico que comprende una primera región de Fc y una segunda región de Fc de un par de Fc de inmunoglobulina y una proteína fisiológicamente activa compuesta de dos o más subunidades diferentes, en donde una o más subunidades de la proteína fisiológicamente activa son enlazadas por separado a uno o más extremos del extremo N-terminal o C-terminal de la primera región de Fc y/o la segunda región de Fc, y los dominios CH3 de la primera región de Fc y la segunda región de Fc son mutados a fin de promover la formación del Fc heterodimérico; además, la presente invención se refiere a una composición farmacéutica que comprende la proteína fusionada al Fc heterodimérico; la proteína fusionada al Fc heterodimérico de conformidad con la presente invención tiene la ventaja de que puede retener la actividad de una proteína fisiológicamente activa de ocurrencia natural, cuyas dos o más subunidades diferentes exhiben actividad fisiológica mediante la formación de un complejo de proteínas, debido a que la proteína fisiológicamente activa puede ser enlazada a un Fc heterodimérico de inmunoglobulina de modo que puede mantenerse la forma y estructura de ocurrencia natural de la proteína fusionada de la misma; cuando se usa la proteína fusionada al Fc heterodimérico de conformidad con la presente invención, existe una ventaja porque la vida media in vivo de la proteína fisiológicamente activa contenida en la proteína fusionada al Fc heterodimérico puede ser incrementada significativamente debido a la larga vida media mediada por el Fc, de modo que varias actividades fisiológicas de la misma in vivo pueden ser de larga duración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160101823 | 2016-08-10 | ||
| KR1020170101594A KR102050463B1 (ko) | 2016-08-10 | 2017-08-10 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010809A true MX2021010809A (es) | 2021-10-01 |
Family
ID=61524969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001651A MX2019001651A (es) | 2016-08-10 | 2017-08-10 | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. |
| MX2021010809A MX2021010809A (es) | 2016-08-10 | 2019-02-08 | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001651A MX2019001651A (es) | 2016-08-10 | 2017-08-10 | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10696722B2 (es) |
| EP (1) | EP3511340A4 (es) |
| JP (3) | JP6993403B2 (es) |
| KR (4) | KR102050463B1 (es) |
| CN (1) | CN110267977A (es) |
| AU (2) | AU2017310163B2 (es) |
| BR (1) | BR112019002394B1 (es) |
| CA (1) | CA3033475A1 (es) |
| MX (2) | MX2019001651A (es) |
| SG (1) | SG11201901071TA (es) |
| ZA (1) | ZA201900772B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6993403B2 (ja) * | 2016-08-10 | 2022-03-03 | アジュ ユニバーシティー インダストリー－アカデミック コーオペレイション ファウンデーション | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 |
| CN111093689A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 免疫刺激融合分子及其用途 |
| EP3753631A4 (en) | 2018-02-14 | 2021-03-17 | Lg Chem, Ltd. | CATALYST LOADING PROCESS AND BUTADIENE PREPARATION PROCESS USING THE SAME |
| CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| PE20211279A1 (es) | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
| AU2020358979A1 (en) | 2019-10-03 | 2022-04-21 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
| JP2024500354A (ja) * | 2020-12-10 | 2024-01-09 | インベンラ， インコーポレイテッド | ヘテロ二量体化のための直交変異 |
| CA3234552A1 (en) * | 2021-10-20 | 2023-04-27 | Synthekine, Inc. | Heterodimeric fc cytokines and uses thereof |
| KR20230157760A (ko) * | 2022-05-10 | 2023-11-17 | 아주대학교산학협력단 | 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
| WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
| WO2024094755A1 (en) * | 2022-11-02 | 2024-05-10 | Synerkine Pharma B.V. | Engineered immunocytokines, fusion polypeptides, and il10 polypeptides |
| WO2024099445A1 (zh) * | 2022-11-10 | 2024-05-16 | 康立泰生物医药(青岛)有限公司 | 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| JP4336452B2 (ja) * | 1997-12-08 | 2009-09-30 | メルク パテント ゲーエムベーハー | 標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US20020055488A1 (en) | 2000-09-21 | 2002-05-09 | Wessels Michael R. | Prevention and treatment of streptococcal and staphylococcal infection |
| US8192744B2 (en) | 2002-08-26 | 2012-06-05 | Ibcc Holding As | Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation |
| JP4730304B2 (ja) | 2004-05-20 | 2011-07-20 | 和光純薬工業株式会社 | ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 |
| CA2610791C (en) | 2005-06-08 | 2015-12-01 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
| JP5466405B2 (ja) | 2006-08-08 | 2014-04-09 | 生化学工業株式会社 | ヒアルロン酸の分子量の測定方法 |
| WO2008089448A2 (en) | 2007-01-19 | 2008-07-24 | Cornell Presearch Foundation, Inc. | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| KR101606386B1 (ko) | 2008-04-02 | 2016-03-25 | 마크로제닉스, 인크. | Ｈｅｒ2/ｎｅｕ-특이적 항체 및 그것의 사용 방법 |
| JP5477287B2 (ja) | 2008-04-15 | 2014-04-23 | 和光純薬工業株式会社 | 新規なヒアルロン酸結合能を有するタンパク質及びこれを用いたヒアルロン酸の測定方法 |
| BRPI1012589A2 (pt) | 2009-04-07 | 2016-03-22 | Roche Glycart Ag | anticorpos bi-específicos anti-erbb-3/anti-c-met |
| CN102573922B (zh) | 2009-08-17 | 2015-08-05 | 罗切格利卡特公司 | 靶向性免疫缀合物 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| DK2560683T4 (da) | 2010-04-23 | 2022-08-29 | Hoffmann La Roche | Fremstilling af heteromultimeriske proteiner |
| BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| EP2691417B1 (en) | 2011-03-29 | 2018-08-01 | Roche Glycart AG | Antibody fc variants |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| RU2617844C2 (ru) | 2011-05-24 | 2017-04-28 | СИМИК АйПи, ЭлЭлСи | Связывающие гиалуроновую кислоту синтетические пептидогликаны, получение и способы использования |
| US9795686B2 (en) | 2012-01-19 | 2017-10-24 | The Johns Hopkins University | Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications |
| MX360110B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
| WO2013163766A1 (en) | 2012-05-04 | 2013-11-07 | Cangene Corporation | ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC |
| BR112015002091A2 (pt) | 2012-08-02 | 2017-12-12 | Hoffmann La Roche | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição |
| PL2880170T3 (pl) | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
| ES2700978T3 (es) | 2012-08-07 | 2019-02-20 | Roche Glycart Ag | Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada |
| EP3878964A1 (en) * | 2012-11-27 | 2021-09-15 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10047167B2 (en) | 2013-03-15 | 2018-08-14 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| PL2992010T3 (pl) | 2013-04-29 | 2021-08-23 | F.Hoffmann-La Roche Ag | Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| KR102603417B1 (ko) | 2014-05-06 | 2023-11-20 | 제넨테크, 인크. | 포유동물 세포를 사용한 이종다량체 단백질의 생산 |
| WO2015197593A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | MULTISPECIFIC NKp46 BINDING PROTEINS |
| AR102521A1 (es) | 2014-11-06 | 2017-03-08 | Hoffmann La Roche | Variantes de región fc con unión de fcrn modificada y métodos de utilización |
| BR112017006591A2 (pt) | 2014-11-06 | 2018-01-16 | Hoffmann La Roche | polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico |
| CN104628870A (zh) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白 |
| PL3331902T3 (pl) | 2015-08-07 | 2021-11-22 | ALX Oncology Inc. | Konstrukty posiadające domenę sirp-alfa lub jej wariant |
| EP4056190A1 (en) | 2015-10-06 | 2022-09-14 | Regents of the University of Minnesota | Therapeutic compounds and methods |
| KR101851380B1 (ko) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 |
| JP6983824B2 (ja) | 2016-07-04 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規抗体フォーマット |
| WO2018030806A1 (ko) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| JP6993403B2 (ja) * | 2016-08-10 | 2022-03-03 | アジュ ユニバーシティー インダストリー－アカデミック コーオペレイション ファウンデーション | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| JP2019014449A (ja) | 2017-07-10 | 2019-01-31 | トヨタ自動車株式会社 | 車両用動力伝達装置 |
| BR112020007154A2 (pt) | 2017-10-20 | 2020-09-29 | F. Hoffmann-La Roche Ag | método para produzir um polipeptídeo e polipeptídeos heterodimérico |
| PE20211279A1 (es) | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
-
2017
- 2017-08-10 JP JP2019506697A patent/JP6993403B2/ja active Active
- 2017-08-10 US US16/323,839 patent/US10696722B2/en active Active
- 2017-08-10 CN CN201780062851.0A patent/CN110267977A/zh active Pending
- 2017-08-10 SG SG11201901071TA patent/SG11201901071TA/en unknown
- 2017-08-10 BR BR112019002394-1A patent/BR112019002394B1/pt active IP Right Grant
- 2017-08-10 KR KR1020170101594A patent/KR102050463B1/ko active IP Right Grant
- 2017-08-10 CA CA3033475A patent/CA3033475A1/en active Pending
- 2017-08-10 EP EP17839824.4A patent/EP3511340A4/en active Pending
- 2017-08-10 AU AU2017310163A patent/AU2017310163B2/en active Active
- 2017-08-10 MX MX2019001651A patent/MX2019001651A/es unknown
-
2019
- 2019-02-06 ZA ZA2019/00772A patent/ZA201900772B/en unknown
- 2019-02-08 MX MX2021010809A patent/MX2021010809A/es unknown
- 2019-11-25 KR KR1020190152270A patent/KR102416411B1/ko active IP Right Grant
-
2020
- 2020-05-28 US US16/886,184 patent/US11692019B2/en active Active
- 2020-05-28 US US16/886,177 patent/US11078249B2/en active Active
-
2021
- 2021-03-03 JP JP2021033816A patent/JP7111855B2/ja active Active
- 2021-11-26 AU AU2021273642A patent/AU2021273642A1/en active Pending
-
2022
- 2022-06-29 KR KR1020220079686A patent/KR102607285B1/ko active Application Filing
- 2022-07-21 JP JP2022116329A patent/JP7488854B2/ja active Active
-
2023
- 2023-05-24 US US18/323,124 patent/US20230416325A1/en active Pending
- 2023-11-23 KR KR1020230164332A patent/KR102652247B1/ko active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010809A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| EA202091342A3 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| CY1120522T1 (el) | Προσδετες τροποποιημενοι μεσω κυκλικης μεταθεσης ως αγωνιστες και ανταγωνιστες | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| PE20170908A1 (es) | VARIANTES DE INTERFERON a2b | |
| EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
| MX2020010910A (es) | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. | |
| AU2019255744A8 (en) | IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof | |
| PE20200303A1 (es) | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer | |
| EA201600190A1 (ru) | Анти-prlr антитела и их применение | |
| MX2021003765A (es) | Proteínas il-12 de fusión a fc heterodimérico. | |
| WO2017201432A3 (en) | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity | |
| NZ737844A (en) | Vista regulatory t cell mediator protein, vista binding agents and use thereof | |
| MX2021003475A (es) | Metodos de purificacion de proteinas. | |
| MX2015005675A (es) | Composiciones y metodos para modular la comunicacion celular. | |
| MX364591B (es) | Antagonistas de il-33 y usos de estos. | |
| PE20170142A1 (es) | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma | |
| EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
| CR20200327A (es) | Proteínas de fusión fc il-22 y métodos de uso | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| MX2020009296A (es) | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. | |
| EA033269B1 (ru) | СОСТАВ ИНГИБИТОРА ИНТЕРЛЕЙКИНА-1 БЕТА (IL-1β) И ЕГО ПРИМЕНЕНИЕ | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE |